Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual GIP/GLP-1 agonists (e.g., tirzepatide) induce significant weight loss and improve glycemic control by acting on multiple pathways including appetite suppression, delayed gastric emptying, and improved adipose tissue health.
GLP-1 agonists like semaglutide are FDA-approved for weight loss and diabetes. They work by mimicking gut hormones to reduce appetite and slow digestion. Clinical trials show significant weight loss (up to ~15% in some ranges) and improved blood sugar. They are typically taken once weekly.
StrongSupportsHIGH confidence
These drugs act by targeting various mechanisms involved in the pathophysiology of obesity and T2DM, and they have been shown to induce significant weight loss and improve glycemic control in obese individuals with T2DM.
Why this rating
Cites multiple clinical trials and FDA approvals.
Source
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi et al. · Molecules · 2023
DOI 10.3390/molecules28073094
narrative_reviewCited 60×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (e.g., Roux-en-Y gastric bypass, sleeve gastrectomy) is an effective treatment for obesity and T2DM, capable of inducing remission of diabetes through both weight-loss-dependent and weight-loss-independent mechanisms.Strong
- Metformin provides modest weight loss (average ~2.1 kg/year) and improves insulin sensitivity, making it a first-line treatment for T2DM, though it is not FDA-approved specifically for weight loss.Strong
- Sustained weight loss of at least 15% significantly improves glycemic control, reduces cardiometabolic risk, and can induce remission of Type 2 Diabetes (T2DM).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →